WEEKLY TOP 5
YOUR WEEKLY UPDATES FROM SHEBA MEDICAL CENTER
Kreiss: Generating Global Economic Growth Through Innovation
During the recent GLOBES/ESG/Israel Discount Bank conference in Tel Aviv, Prof. Yitshak Kreiss, Director General of Sheba Medical Center, outlined his vision for the hospital’s evolving agenda.
“Our doctors are primed to create global impact”, Prof. Kreiss revealed. “We are connecting trade and employment abroad with what is happening inside Sheba. If we succeed in bringing additional returns due to our proximity, we have brought economic growth. In healthcare, there is ongoing potential for economic growth. We gener
ate Sheba’s growth through innovation. What is needed? Data. Israel is the most advanced country in this regard. For an Israeli healthcare startup, data, patients, doctors, and the market are necessary.”
INNOVATIVE TISSUE ENGINEERING AT SHEBA
Join Us for the REACT Event
Sheba Tackles Post Covid Lung Problems
Why Isn’t a Malaria Vaccine Available in the USA?
SPRI GENERATES GLOBAL IMPACT
More Posts
Sheba Medical Center Join General Catalyst’s Health Assurance Ecosystem to Advance Innovative Medical Solutions
General Catalyst is a leading US-based venture capital firm specializing in early-stage and growth investments across various industries, including technology, healthcare, and consumer goods. Known for its strategic approach and deep industry knowledge, General Catalyst not only provides financial support to entrepreneurs but also offers valuable guidance and resources to help them navigate the complex challenges of building and expanding their businesses.
Revolutionizing Diagnostic Medicine: Sheba Partners with Aidoc for Early Intracerebral Hemorrhages Detection
A pioneer in the application of AI in clinical settings, Sheba has played a central role in the development of numerous solutions that are now used across the globe. This includes Aidoc, which was founded at Sheba and now provides advanced AI decision-support tools to many of the world’s leading medical centers.
Sheba and Vidac Pharma Partner to Overcome the Warburg Effect
CAR T-cell therapy is a revolutionary blood cancer treatment that involves extracting and genetically engineering a patient’s T-cells to produce chimeric antigen receptors, or CARs, that facilitate the targeting and elimination of malignant cells.
